TRANSGENIC GROUP (2342) FY2026 Q3 Earnings Report

Quick View

Executive Summary

Cumulative results for the first three quarters showed a return to operating profitability from a loss in the same period of the previous year, confirming that profitability has bottomed out. Revenue declined slightly to ¥9.695B (down 1.1% YoY), while Operating Income rose to ¥0.104B (versus a loss of ¥0.126B in the same period of the previous year), Ordinary Income to ¥0.093B (versus a loss of ¥0.162B), and Net Income attributable to owners of the parent to ¥0.028B (versus a loss of ¥0.291B), with all three turning profitable. The principal factors supporting higher earnings despite lower revenue were a 1.6pt improvement in gross profit margin and a 5.5% reduction in SG&A expenses.

Factors Affecting Earnings

【Revenue】Revenue was ¥9.695B, down 1.1% YoY. The core Investment and Consulting Business declined 3.8% to ¥8.265B and accounted for 85.2% of total revenue, while the Drug Discovery Support Business grew 17.2% to ¥1.431B, partially offsetting the decline. The consolidated revenue decrease was attributable to trends in projects in the core business.

【Profit and Loss】Operating Income was ¥0.104B, turning profitable from a loss of ¥0.126B in the same period of the previous year. The primary factors were an improvement in gross profit margin from 17.4% to 19.0% and a 5.5% reduction in SG&A expenses. Ordinary Income was ¥0.093B. Among non-operating items, interest expense of ¥0.036B exceeded interest income of ¥0.002B and was a factor depressing earnings, while foreign exchange gains of ¥0.021B provided support. In extraordinary items, a gain on the sale of investment securities of ¥0.138B was recorded as extraordinary income, while extraordinary losses of ¥0.194B, including ¥0.034B in business restructuring expenses, were recorded, leaving Profit Before Tax at ¥0.074B. The effective tax rate was high at 87.2%, constraining the conversion to Net Income of ¥0.028B. Despite lower revenue, the results represented higher earnings accompanied by improved profitability.

Segment Analysis

The Investment and Consulting Business reported Revenue of ¥8.265B (down 3.8% YoY), Segment Profit of ¥0.370B (up 1.4%), and a profit margin of 4.5%, broadly unchanged from the same period of the previous year. It maintained its profit level despite lower revenue and remains the main contributor to consolidated earnings. The Drug Discovery Support Business reported Revenue of ¥1.431B (up 17.2%) and a Segment Loss of ¥0.127B, narrowing its loss by ¥0.203B from the ¥0.330B loss recorded in the same period of the previous year. Its margin improved from negative 27.1% to negative 8.8%. Although fixed-cost absorption is progressing alongside revenue growth, the business remains a structural factor depressing the consolidated operating profit margin. Company-wide expenses were ¥0.139B, down from ¥0.161B in the same period of the previous year.

Key Financial Indicators

【Profitability】The operating profit margin was 1.1%, improving 2.4pt from negative 1.3% in the same period of the previous year, although the absolute level remains low. The net profit margin remained at just 0.3%; the gross profit margin of 19.0% and EBIT margin of 1.1% were also low, indicating limited resilience to fluctuations in costs and project profitability.【Cash Flow Quality】The effective tax rate was high at 87.2%, constraining the conversion of Profit Before Tax of ¥0.074B into Net Income of ¥0.028B. Inventories were ¥1.637B, including ¥1.020B in work in process, and inventory days exceeded 90 days on an annualized basis.【Investment Efficiency】Annualized ROE was 0.8% and annualized ROIC was 1.4%, both remaining at low levels. DuPont analysis shows ROE as a product of a 0.3% net profit margin, 1.25x total asset turnover, and 2.07x financial leverage, with the low net profit margin acting as the limiting factor.【Financial Soundness】The Equity Ratio was 48.4% and the current ratio was 177.4%, both healthy levels. However, the interest coverage ratio was 2.86x and the short-term debt ratio was 55.3%, requiring attention from a funding perspective. Short-term borrowings increased 80.1% YoY to ¥1.225B.

Cash Flow Analysis

Although detailed disclosure of the statement of cash flows is unavailable, funding trends can be assessed from changes in the balance sheet. Cash and deposits were ¥2.242B, down ¥0.313B from ¥2.555B in the same period of the previous year, while short-term borrowings increased ¥0.545B YoY to ¥1.225B and investment securities increased ¥0.205B to ¥0.313B. Cash and deposits exceeded short-term borrowings by ¥1.017B, indicating sufficient liquidity for short-term funding needs. Nevertheless, the simultaneous increase in reliance on short-term borrowings and decrease in cash balances warrants close monitoring of the allocation of funds to working capital and the acquisition of investment securities.

Quality of Earnings

Ordinary Income of ¥0.093B resulted from Operating Income of ¥0.104B being offset by non-operating income, including foreign exchange gains of ¥0.021B, and non-operating expenses, including interest expense of ¥0.036B, and was therefore composed primarily of business-related earnings. Meanwhile, Profit Before Tax of ¥0.074B reflected a non-recurring extraordinary gain of ¥0.138B on the sale of investment securities and extraordinary losses of ¥0.194B, including ¥0.034B in business restructuring expenses. Accordingly, the final profit level of ¥0.028B was strongly affected by extraordinary gains and losses. The effective tax rate of 87.2% indicates a heavy corporate tax burden relative to Profit Before Tax, and it is not appropriate to assess the current period’s profit level solely on the basis of recurring earnings power. Comprehensive Income was ¥0.163B, of which ¥0.181B was attributable to owners of the parent, exceeding Net Income of ¥0.028B. This was attributable to a ¥0.145B contribution from valuation differences on securities and must be distinguished from the earnings power of the core business.

Earnings Forecasts and Guidance

Against the full-year company forecasts of Revenue of ¥13.50B, Operating Income of ¥0.15B, Ordinary Income of ¥0.09B, and EPS of ¥2.40, the revenue progress rate was 71.8%, below the standard 75%. Ordinary Income was ¥0.093B, representing a progress rate of 103.3% and already exceeding the full-year forecast. However, this includes non-operating factors such as foreign exchange gains, so it does not correspond directly to an improvement in core earnings power. Meanwhile, the progress rates for Operating Income and Net Income were 69.3% and 70.0%, respectively, both somewhat behind the standard level. An increase of approximately ¥0.046B in Operating Income during Q4 would serve as a benchmark for achieving the plan.

Shareholder Returns

The Q2 dividend was ¥0 per share, and the full-year company forecast for annual dividends is also ¥0, resulting in an effective Payout Ratio of 0%. The no-dividend policy may help preserve financial flexibility under the current conditions of a 1.1% operating profit margin and 2.86x interest coverage ratio. No data on share repurchases has been disclosed.

Risk Factors

1. Continued decline in the core business: The Investment and Consulting Business, which represents 85.2% of consolidated revenue, declined 3.8% YoY. Trends in projects in this business have a significant impact on consolidated performance.

2. Concentration in funding sources: The short-term debt ratio was 55.3%, while short-term borrowings increased 80.1% YoY to ¥1.225B. The interest coverage ratio remained at only 2.86x, indicating relatively high sensitivity to interest rate increases and changes in refinancing conditions.

3. Profitability challenges in the Drug Discovery Support Business: Although the business achieved revenue growth, its Segment Loss continued at ¥0.127B. Under a low-profitability structure characterized by a 19.0% gross profit margin and a 1.1% operating profit margin, project mix and cost fluctuations have a significant impact on consolidated earnings.

Industry Benchmark (For Reference; Company Research)

Profitability and Returns

Profitability was significantly below the industry median, with both operating and net profit margins ranking relatively low within the industry.

Growth and Capital Efficiency

The revenue growth rate was also significantly below the industry median and remained below the lower bound of the IQR.

※Source: Company research

Key Takeaways from the Earnings Results

1. Operating earnings turned from a loss of ¥0.126B in the same period of the previous year to a profit of ¥0.104B. The earnings data indicates that an improvement in gross profit margin and reductions in SG&A expenses were central to the recovery.

2. The Investment and Consulting Business remains the core source of profit but experienced a revenue decline, while the Drug Discovery Support Business achieved revenue growth and a narrower loss but remained unprofitable. The contrast in earnings trends between the two businesses defines the structure of consolidated performance.

3. Ordinary Income exceeded the full-year forecast with a progress rate of 103.3%, while the progress rates for Operating Income and Net Income were 69.3% and 70.0%, respectively, lagging behind the plan. The upside in Ordinary Income includes non-operating factors such as foreign exchange gains and must be assessed separately from progress in core earnings power.

Theoretical Share Price (Reference Value)

Sensitivity: ¥213–¥225 at ±1% for the cost of equity, and ¥217–¥221 at ±0.1 for ω.

Notes:

• Net Income is substantially compressed relative to Operating Income due to tax burdens, acquisition-related expenses, and non-controlling interests, among other factors (Net Income ÷ Operating Income 27%). This value reflects that compression at face value; if the factors are temporary, normalized earnings power may be higher.
• Because forecast ROE is below the cost of equity, the theoretical value is below Book Value per Share.
• Net assets as of the quarter-end are used, resulting in a timing difference from the full-year forecast.

(Calculation model: Residual Income Model (Ohlson-type; explicit 5-year fade) / Interest rate reference month: 2026-08 / Mechanically calculated value based solely on publicly disclosed data; it is not a forecast of the market share price or a recommendation of any specific investment action, and does not predict or guarantee the future share price.)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings summary data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility, after consulting with a professional as necessary.

---End of Report---